Provided by Tiger Fintech (Singapore) Pte. Ltd.

Galectin Therapeutics

1.68
-0.0800-4.55%
Post-market: 1.740.0600+3.57%19:36 EDT
Volume:197.19K
Turnover:335.95K
Market Cap:105.44M
PE:-2.31
High:1.79
Open:1.75
Low:1.64
Close:1.76
Loading ...

Company Profile

Company Name:
Galectin Therapeutics
Exchange:
NASDAQ
Establishment Date:
2000
Employees:
14
Office Location:
4960 Peachtree Industrial Boulevard,Suite 240,Norcross,Georgia,United States
Zip Code:
30071
Fax:
- -
Introduction:
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Directors

Name
Position
Joel Lewis
President and Chief Executive Officer and Director
Richard E. Uihlein
Chairman of the Board
Benjamin S. Carson, Sr.
Director
Elissa J. Schwartz
Director
Gilbert F. Amelio
Director
Gilbert S. Omenn
Director
Harold Shlevin
Director
Kary Eldred
Director
Kevin D. Freeman
Director
Marc Rubin
Director
Richard A. Zordani
Director

Shareholders

Name
Position
Joel Lewis
President and Chief Executive Officer and Director
Jack W. Callicutt
Chief Financial Officer
Pol F. Boudes
Chief Medical Officer